New drug ACR246 enters early human testing for advanced cancers
NCT ID NCT06238401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, ACR246, in about 77 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look for any signs that it might shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tumor Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Email: •••••@•••••
-
Shandong First Medical University affiliated Cancer Hospital of Shandong
RECRUITINGShandong, Jinan, 250117, China
-
ShangHai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
-
ShangHai Sixth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, 200233, China
-
Zhejiang Cancer Hospital
RECRUITINGZhejiang, Hangzhou, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.